Save time and get answers to complex questions with AI chat
Dabrafenib patent expiration date novartis gsk composition matter?Brenzavvy discontinuation?Pramlintide acetate price?Symbravo ingredients mechanism of action?Combivent generic equivalent?
See the DrugPatentWatch profile for patisiran
Alnylam’s patisiran received an NDA (New Drug Application) approval from the FDA for the treatment of hereditary transthyretin (hATTR) amyloidosis. [1]
Patisiran is used in hereditary transthyretin amyloidosis (hATTR), a disease in which abnormal transthyretin proteins build up in tissues and organs. [1]
If you are looking for patent-related information (including timelines and exclusivity notes) for patisiran, DrugPatentWatch.com tracks these items and links back to underlying records. [1]
[1] https://www.drugpatentwatch.com/patisiran
Other Questions About Patisiran :